Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 8, 2023 -- Tirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle intervention, according to a study published online Oct. 15 in Nature Medicine to coincide with the annual meeting of The Obesity Society (ObesityWeek), held from Oct. 14 to 17 in Dallas.
Thomas A. Wadden, Ph.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues randomly assigned (1:1) 579 adults with body mass index ≥30 or ≥27 kg/m2 and at least one obesity-related complication (excluding diabetes), who achieved ≥5.0 percent weight reduction after a 12-week intensive lifestyle intervention, to the tirzepatide maximum tolerated dose (10 or 15 mg) or placebo once weekly for 72 weeks.
The researchers found that the coprimary end point of additional mean percent weight change from randomization to week 72 was met with changes of −18.4 percent with tirzepatide and 2.5 percent with placebo. For the additional coprimary end point of the percentage of participants achieving additional weight reduction ≥5 percent, 87.5 percent of participants taking tirzepatide and 16.5 percent taking placebo achieved this threshold (odds ratio, 34.6 percent). Gastrointestinal events, most being mild to moderate in severity, were the most common adverse events seen with tirzepatide.
"The additional weight loss produced further improvements, compared with placebo, in multiple measures of health, including waist circumference, blood pressure, cholesterol and triglycerides, blood sugar, and physical functioning," Wadden said in a statement.
Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.